Loading
NASDAQHealthcareBiotechnology
Latest quote
$25.37
+$0.77 · +3.13%
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Regular session
$25.37
+$0.77 · +3.13%
Regular session · ET · Market data may be delayed.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Day range
Current $25.37
52-week range
Current $25.37
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
56
Fair Value
Sentiment
67
Bullish
Risk
56
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Day range
Current $25.37
52-week range
Current $25.37
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 139.74M USD | 63.52M USD | 377.71M USD | 60.92M USD | 51.84M USD |
| Cost of goods sold | 22.29M USD | 367.56M USD | — | 311.59M USD | 232.13M USD |
| Gross profit | 117.45M USD | −304.04M USD | 377.71M USD | −250.67M USD | −180.29M USD |
| Research and development | 409.62M USD | 367.56M USD | 437.38M USD | 311.59M USD | 387.09M USD |
| Selling, general, and administrative | 113.82M USD | 111.53M USD | 116.81M USD | 87.81M USD | 57.22M USD |
| Operating expenses | 501.14M USD | 111.53M USD | 554.19M USD | 87.81M USD | 212.18M USD |
| Interest income | — | 49.09M USD | 46.68M USD | 15.3M USD | — |
| Interest expense | 43.73M USD | — | — | — | — |
| Depreciation and amortization | 22.29M USD | 21.93M USD | 20.01M USD | 14.15M USD | 7.45M USD |
| Operating income | −383.69M USD | −415.57M USD | −176.49M USD | −338.48M USD | −392.47M USD |
| Net income | −79.99M USD | −376.74M USD | −132.53M USD | −289.09M USD | −370.64M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK155.92M2.27%5.56B USD0.75%$89.25+1.88%
Vanguard Morningstar Total Stock Market ETFVTI96.6M0.00%2.3T USD0.03%$381.05+0.39%
State Street SPDR S&P Biotech ETFXBI87.61M0.87%10.11B USD0.35%$152.01+1.82%
Vanguard Morningstar Small-Cap ETFVB69.62M0.04%185.3B USD0.03%$288.36+0.25%
ARK Genomic Revolution ETFARKG66.35M3.24%1.56B USD0.75%$50.655+2.77%
iShares Russell 2000 ETFIWM64.26M0.08%77.7B USD0.19%$278.3+0.26%
Vanguard Morningstar Small-Cap Growth ETFVBK40.1M0.09%44.7B USD0.05%$342.64+0.60%
Vanguard Extended Market ETFVXF34.08M0.03%95.4B USD0.05%$234.15+0.44%ARK Innovation ETFARKKVanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.